Regency Capital Management Inc. DE Takes $937,000 Position in Zoetis Inc. (NYSE:ZTS)

Regency Capital Management Inc. DE purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 5,688 shares of the company's stock, valued at approximately $937,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ZTS. Navigoe LLC bought a new position in shares of Zoetis in the fourth quarter worth approximately $30,000. Cornerstone Planning Group LLC raised its holdings in Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after acquiring an additional 88 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its stake in Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after purchasing an additional 120 shares during the period. Murphy & Mullick Capital Management Corp bought a new position in shares of Zoetis during the 4th quarter valued at about $44,000. Finally, Sound Income Strategies LLC grew its holdings in Zoetis by 141.4% during the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after buying an additional 164 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the transaction, the executive vice president directly owned 15,129 shares in the company, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by insiders.

Zoetis Stock Down 0.9%

Shares of NYSE ZTS traded down $1.29 during midday trading on Monday, reaching $147.31. 2,996,578 shares of the company's stock traded hands, compared to its average volume of 2,624,290. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 1.12. The company has a market cap of $65.59 billion, a price-to-earnings ratio of 24.68, a P/E/G ratio of 2.46 and a beta of 0.91. The stock's 50 day simple moving average is $160.77 and its 200-day simple moving average is $161.42. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. Zoetis's revenue was up 1.4% compared to the same quarter last year. During the same period last year, the firm earned $1.38 earnings per share. On average, analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.36%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's payout ratio is 35.91%.

Analysts Set New Price Targets

ZTS has been the subject of a number of analyst reports. Piper Sandler increased their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, May 12th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and decreased their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $180.00 to $155.00 in a research note on Thursday. Finally, UBS Group reduced their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $204.63.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.